Dallas, Texas 02/13/2014 (FINANCIALSTRENDS) – In a recent development Dan Mitchell has been included into board of directors list of ACRA Biopharma (NASDAQ:ABIO). He has been assigned with the responsibility to serve for the audit and nominating as well as corporate governance committees of the board of directors. Mr. Mitchell formed a venture capital firm in 1997 by the name of Sequel Ventures Partners, L.L.C and also acted as its manager as well as founder. Before he founded Sequel Ventures Mr. Mitchell also founded another firm by the name of Capital Health Venture Partners in 1986.
He is an MBA from the University of California at Berkeley and has got years of vast work experience with him. His appointment is seen as a positive point and after his appointment the company released a press statement in which it was told that the company believes that his inclusion into the company should be seen as another step towards growth and prosperity. During the last trading session the shares closed at $1.79 and its 52 week high is $3.93 and its 52 week low is $1.13. if we talk about the current market capitalization of this company then it comes out to be $28.06 million.
An Overview of the Company
ACRA Biopharma (NASDAQ:ABIO) is basically a biopharmaceutical company that is responsible for the development of the genetically-targeted therapies for different types of cardiovascular diseases. One of the key products that are offered by the company is called as Gencaro which is basically bucindolol hydrochloride and is a pharmacologically beta blocker, investigational and mild vasodilator being developed mainly for atrial fibrillation.
The company has also identified some key and common genetic variations that can predict individual patient’s response to their key product that is Gencaro. The company has also done tie-up with Medtronic Inc. for conducting Genetic-AF trail.